This relevance is highlighted by the profound restriction of GR binding sites to open chromatin sites in AR-positive prostate cancer cells (Figure 3E) (57), suggesting that GR replaces AR activity and drives enzalutamide resistance from these open chromatin sites. This evidence concerns the gene AR and prostate carcinoma.